Ziv-aflibercept

(Zaltrap®)

Zaltrap®

Drug updated on 11/9/2023

Dosage FormInjection (intravenous; 100 mg/4 mL (25 mg/mL), 200 mg/8 mL (25 mg/mL))
Drug ClassVascular endothelial growth factor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use in combination with FOLFIRI (fluorouracil, leucovorin, irinotecan) for the treatment of metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin regimen.

Product Monograph / Prescribing Information

Document TitleYearSource
Zaltrap (ziv-aflibercept) Prescribing Information.2020Sanofi-Aventis U.S. LLC, Bridgewater, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis. 2023Medicine
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety. 2023Critical Reviews in Oncology/Hematology
Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment. 2022Frontiers in Pharmacology
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials2022Journal of Clinical Pharmacy and Therapeutics
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: a systematic review and PRISMA-compliant single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.2021Journal of Clinical Pharmacy and Therapeutics
Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. 2021Molecular Diagnosis and Therapy
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: a systematic review and PRISMA-cCompliant single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.2021Journal of Clinical Pharmacy and Therapeutics
Efficacy and safety of regorafenib in combination with chemotherapy as second-line treatment in patients with metastatic colorectal cancer: a network meta-analysis and systematic literature review.2020Advances in Therapy

Clinical Practice Guidelines

Document TitleYearSource
Treatment sequencing in metastatic colorectal cancer. 2019European Journal of Cancer